|
顯示項目 230921-230945 / 2346288 (共93852頁)
<< < 9232 9233 9234 9235 9236 9237 9238 9239 9240 9241 > >>
每頁顯示[10|25|50]項目
| 衛生福利部國家中醫藥研究所 |
2013 |
BPR0C305, an orally active microtubule-disrupting anticancer agent
|
Li, Wen-Tai; Yeh, Teng-Kuang; Song, Jen-Shin; Yang, Yung-Ning; Chen, Tung-Wei; Lin, Chi-Hung; Chen, Ching-Ping; Shen, Chien-Chang; Hsieh, Chih-Chien; Lin, Heng-Liang; Chao, Yu-Sheng; Chen, Chiung-Tong |
| 國家衛生研究院 |
2004-07-01 |
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo
|
Kuo, CC; Hsieh, HP; Pan, WY; Chen, CP; Lion, JP; Lee, SJ; Chang, YL; Chen, LT; Chen, CT; Chang, JY |
| 國家衛生研究院 |
2012-01 |
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
|
Lin, WH;Jiaang, WT;Chen, CW;Yen, KJ;Hsieh, SY;Yen, SC;Chen, CP;Chang, KY;Chang, CY;Chang, TY;Huang, YL;Yeh, TK;Chao, YS;Chen, CT;Hsu, JT |
| 國立交通大學 |
2014-12-08T15:22:05Z |
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
|
Lin, W-H; Jiaang, W-T; Chen, C-W; Yen, K-J; Hsieh, S-Y; Yen, S-C; Chen, C-P; Chang, K-Y; Chang, C-Y; Chang, T-Y; Huang, Y-L; Yeh, T-K; Chao, Y-S; Chen, C-T; Hsu, J. T-A |
| 國家衛生研究院 |
2012-11 |
BPR1J271, a novel FLT3 inhibitor for treating acute myeloid leukemia
|
Chen, CT;Lin, WH;Chou, LH;Chen, CP;Yen, SC;Huang, YL;Yeh, TK;Hsu, JTA;Jiaang, WI;Chao, YS |
| 國家衛生研究院 |
2018-08-24 |
BPR1J373, a novel multi-targeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor
|
Tsai, HJ;Jiaang, WT;Shih, NY;Fletcher, JA;Lin, MJ;Yang, MY;Chen, CT;Hsu, TJ;Wu, CC;Lin, HY;Chen, LT |
| 國家衛生研究院 |
2018-08-24 |
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor
|
Tsai, HJ;Jiaang, WT;Shih, NY;Fletcher, JA;Lin, MJ;Yang, MY;Chen, CT;Hsu, TAJ;Wu, CC;Lin, HY;Chen, LT |
| 國立成功大學 |
2018 |
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor
|
Tsai, H.-J.;Jiaang, W.-T.;Shih, N.-Y.;Fletcher, J.A.;Lin, M.-J.;Yang, M.-Y.;Chen, Chen C.-T.;Hsu, T.-A.J.;Wu, C.-C.;Lin, H.-Y.;Chen, L.-T. |
| 國家衛生研究院 |
2016-10 |
BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia
|
Chen, LT;Chen, CT;Jiaang, WT;Chen, TY;Butterfield, JH;Shih, NY;Hsu, JT;Lin, HY;Lin, SF;Tsai, HJ |
| 國立成功大學 |
2016-10-01 |
BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia
|
Chen, Li-Tzong; Chen, Chiung-Tong; Jiaang, Weir-Torn; Chen, Tsai-Yun; Butterfield, Joseph H.; Shih, Neng-Yao; Hsu, John Tsu-An; Lin, Hui-You; Lin, Sheng-Fung; Tsai, Hui-Jen |
| 國家衛生研究院 |
2011-08 |
BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells
|
Cheung, CH;Lin, WH;Hsu, TA;Hour, TC;Yeh, TK;Ko, S;Lien, TW;Coumar, MS;Liu, JF;Lai, WY;Shiao, HY;Lee, TR;Hsieh, HP;Chang, JY |
| 國立成功大學 |
2011-08-24 |
BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells
|
Cheung, Chun Hei Antonio; Lin, Wen-Hsing; Hsu, John Tsu-An; Hour, Tzyh-Chyuan; Yeh, Teng-Kuang; Ko, Shengkai; Lien, Tzu-Wen; Coumar, Mohane Selvaraj; Liu, Jin-Fen; Lai, Wen-Yang; Shiao, Hui-Yi; Lee, Tian-Ren; Hsieh, Hsing-Pang; Chang, Jang-Yang |
| 國家衛生研究院 |
2011-09-23 |
BPR1K653, a novel Aurora Kinase Inhibitor, exhibits potent anti-proliferative activity in P-gp170 (MDR1)-mediated VX680-resistant cancer cells in vitro and in vivo
|
Hsieh, HP;Cheung, CHA;Lin, WH;Hsu, TA;Coumar, MS;Chao, YS;Chang, JY |
| 國家衛生研究院 |
2019-07-03 |
BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine
|
Chao, PK;Chang, HF;Chang, WT;Yeh, TK;Ou, LC;Chuang, JY;Tsu-An Hsu, J;Tao, PL;Loh, HH;Shih, C;Ueng, SH;Yeh, SH |
| 國立成功大學 |
2020 |
BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine
|
Chao, P.-K.;Chang, H.-F.;Chang, W.-T.;Yeh, T.-K.;Ou, L.-C.;Chuang, J.-Y.;Tsu-An, Hsu J.;Tao, P.-L.;Loh, H.H.;Shih, C.;Ueng, S.-H.;Yeh, S.-H. |
| 國家衛生研究院 |
2010-01 |
BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses
|
Shih, SR;Horng, JT;Poon, LL;Chen, TC;Yeh, JY;Hsieh, HP;Tseng, SN;Chiang, C;Li, WL;Chao, YS;Hsu, JT |
| 國立交通大學 |
2014-12-08T15:07:38Z |
BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses
|
Shih, Shin-Ru; Horng, Jim-Tong; Poon, Leo L. M.; Chen, Tzu-Chun; Yeh, Jiann-Yih; Hsieh, Hsing-Pang; Tseng, Sung-Nain; Chiang, Chiayn; Li, Wan-Ling; Chao, Yu-Sheng; Hsu, John T. -A. |
| 國家衛生研究院 |
2015-08 |
BPR2P001S0, a Coumarin derivative, induced cell cycle arrest in A549 through inhibiting PDPK1 activity
|
Lin, PH;Jao, TM;Hung, YL;Hsieh, HP;Yang, YC;Chang, SY |
| 國家衛生研究院 |
2024-04 |
BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir
|
Tang, WF;Chang, YH;Lin, CC;Jheng, JR;Hsieh, CF;Chin, YF;Chang, TY;Lee, JC;Liang, PH;Lin, CY;Lin, GH;Cai, JY;Chen, YL;Chen, YS;Tsai, SK;Liu, PC;Yang, CM;Shadbahr, T;Tang, J;Hsu, YL;Huang, CH;Wang, LY;Chen, CC;Kau, JH;Hung, YJ;Lee, HY;Wang, WC;Tsai, HP;Horng, JT |
| 國家衛生研究院 |
2020-08 |
BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification
|
Chi, YH;Chang, CP;Ke, YY;Lin, WH;Wang, WP;Tsai, CH;Chen, YT;Su, YJ;Hung, MC;Wu, ZW;Wu, MH;Yeh, TK;Chen, CP;Song, JS;Chen, CT;Shih, C |
| 國家衛生研究院 |
2021-01 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy
|
Chen, YY;Lo, CF;Chiu, TY;Hsu, CY;Yeh, TK;Chen, CP;Huang, CL;Huang, CY;Wang, MH;Huang, YC;Ho, HH;Chao, YS;Shih, JC;Tsou, LK;Chen, CT |
| 國家衛生研究院 |
2019-07 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy
|
Hsu, CY;Chen, YY;Lo, CF;Chiu, TY;Chen, CP;Huang, CL;Huang, CY;Wang, MH;Chao, YS;Shih, JC;Yeh, TK;Tsou, LK;Chen, CT |
| 國立中山大學 |
2012-08-20 |
BPR實施方法論 － 以A個案公司為例
|
吳則蔚 |
| 元智大學 |
1994 |
BPR組織特徵之認知的實證研究
|
陳建志 |
| 國立中山大學 |
2015-07-27 |
BPR結合MDA於外包管理系統開發之研究－以高爾夫球頭製造商為例
|
何佩蓉 |
顯示項目 230921-230945 / 2346288 (共93852頁)
<< < 9232 9233 9234 9235 9236 9237 9238 9239 9240 9241 > >>
每頁顯示[10|25|50]項目
|
